iTolerance
Regenerative medicine platform enabling cell and tissue therapies without immunosuppression
- Sector
- Biotech
- Headquarters
- MIAMI, FL
- Founded
- 2020
- Latest Form D
- $5.2M, Aug 2021
- Total capital
- $5.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.2M
- 1 Form D · last Aug 2021
- 62 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$5.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Anthony JapoulExecutive Officer, DirectorNamed in SEC Form D filings
- Anthony JapourExecutive Officer, DirectorNamed in SEC Form D filings
- Cameron GrayExecutive Officer, DirectorNamed in SEC Form D filings
- Camillo A. RicordiExecutive OfficerNamed in SEC Form D filings
- Dennis A. HesterExecutive OfficerNamed in SEC Form D filings
- Peter A. KienerExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
- Timothy A. BraunsExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 3- PendingTransient Sirolimus With Fasl MicrogelsUSPTOApplication 18865252
- PendingTransient Sirolimus With Fasl MicrogelsUSPTOApplication PCTUS2023066897
- PendingTransient Sirolimus With Fasl MicrogelsUSPTOApplication 63364607
Related companies, and why
- Dialectic Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Propanc Biopharma, Inc.Similar federal contract value in Biotech · null in contracts
- CHINA PHARMA HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- IZUN PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts
- Alterome TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Outpace BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .